Home | Business News | Browse by Publication | P | PR Newswire

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine.

Article Excerpt
WASHINGTON, June 7 /PRNewswire/ -- BARI-2D is a useful and focused trial that builds on the body of scientific knowledge physicians use to provide the best possible care for diabetic patients with chronic stable angina and to evaluate their treatment options. The Society for Cardiovascular Angiography and Interventions (SCAI) encourages healthcare providers to apply the findings of BARI-2D, when appropriate, to their patients, as studied in this trial. BARI-2D specifically applies to those with carefully controlled diabetes, multi-vessel but stable coronary artery disease (CAD), and few heart disease symptoms. This trial does not answer the question of whether all patients with diabetes and multi-vessel CAD might be better treated with optimal medical therapy (OMT) plus either percutaneous coronary intervention (PCI) or bypass surgery (CABG).

Since the BARI-2D study enrolled a very small subset of CAD patients with diabetes, SCAI looks forward to additional data from the upcoming FREEDOM trial, which may shed more light on revascularization options for this...